Literature DB >> 2197813

Coagulase-negative staphylococci: incidence, pathogenicity, and treatment in the 1990s.

E M Bailey1, T D Constance, L M Albrecht, M J Rybak.   

Abstract

Coagulase-negative staphylococci (CNS), which historically have been viewed as contaminants when recovered in culture media, are now recognized as opportunistic pathogens of increasing importance in hospital-acquired infections. They are frequently found colonizing prosthetic devices and intravenous lines. CNS are capable of producing a variety of infections including deep-seated infections such as endocarditis and meningitis. Staphylococcus epidermidis is the most commonly isolated CNS and it appears to be the most resistant to antibiotics, making antimicrobial therapy challenging. Treatment of the infection will very often require removal of a prosthetic device, if present. An adequate infection control program is imperative in prophylaxis against this infection.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2197813     DOI: 10.1177/106002809002400715

Source DB:  PubMed          Journal:  DICP        ISSN: 1042-9611


  4 in total

1.  Antimicrobial activity of MDL 62,873, a semisynthetic derivative of teicoplanin, in vitro and in experimental infections.

Authors:  M Berti; G Candiani; M Borgonovi; P Landini; F Ripamonti; R Scotti; L Cavenaghi; M Denaro; B P Goldstein
Journal:  Antimicrob Agents Chemother       Date:  1992-02       Impact factor: 5.191

2.  Fever and 'negative' blood cultures in an elderly woman.

Authors:  J C Graham; N Kennedy; F J Nye
Journal:  Postgrad Med J       Date:  1997-06       Impact factor: 2.401

3.  Evaluation of procedures for decontaminating ultrasound probes.

Authors:  Shunji Hayashi; Harumi Koibuchi; Nobuyuki Taniguchi; Yoshikazu Hirai
Journal:  J Med Ultrason (2001)       Date:  2011-10-26       Impact factor: 1.314

Review 4.  Update on clinical significance of coagulase-negative staphylococci.

Authors:  W E Kloos; T L Bannerman
Journal:  Clin Microbiol Rev       Date:  1994-01       Impact factor: 26.132

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.